Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Liabilities (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Total Liabilities for 12 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 38.32% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Sep 2025, down 38.32%, and an annual FY2024 reading of $7.3 million, up 4.17% over the prior year.
  • Total Liabilities was $3.1 million for Q3 2025 at Arcadia Biosciences, down from $3.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $28.1 million in Q2 2021 and bottomed at $3.1 million in Q3 2025.
  • Average Total Liabilities over 5 years is $10.1 million, with a median of $8.1 million recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 70.7% in 2022, then skyrocketed 60.31% in 2023.
  • Year by year, Total Liabilities stood at $12.7 million in 2021, then plummeted by 36.94% to $8.0 million in 2022, then dropped by 12.72% to $7.0 million in 2023, then rose by 4.17% to $7.3 million in 2024, then crashed by 56.94% to $3.1 million in 2025.
  • Business Quant data shows Total Liabilities for RKDA at $3.1 million in Q3 2025, $3.3 million in Q2 2025, and $4.1 million in Q1 2025.